Vericel Corporation Common Stock VCEL
i
Market dataready · fetched 2026-11-12T00:50:26.165Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:30:04.679836805Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T00:50:25.415540+00:00
Vericel Corporation Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 79.04 | 209.8% | 35.9% | 55.29 | 85.9% | 10.0% |
| 30Δ | 70.65 | 159.8% | 21.9% | 56.34 | 82.6% | 8.7% |
| 35Δ | 57.39 | 79.4% | 7.5% | |||
| 40Δ | 58.44 | 76.1% | 6.3% | |||
| 45Δ | 59.49 | 72.9% | 5.0% | |||
| 50Δ | 60.44 | 70.8% | 4.1% | |||
| 55Δ | 61.30 | 69.7% | 3.6% | |||
| 60Δ | 62.17 | 68.7% | 3.0% | |||
| 65Δ | 63.03 | 67.7% | 2.5% | |||
| 70Δ | 63.89 | 66.7% | 1.9% | |||
| 75Δ | 64.76 | 65.6% | 1.4% | |||
| 80Δ | 68.02 | 84.6% | 1.2% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 79.04
- IV
- 209.8%
- B/E move
- 35.9%
- Pseudo strike
- 55.29
- IV
- 85.9%
- B/E move
- 10.0%
30Δ
- Pseudo strike
- 70.65
- IV
- 159.8%
- B/E move
- 21.9%
- Pseudo strike
- 56.34
- IV
- 82.6%
- B/E move
- 8.7%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 57.39
- IV
- 79.4%
- B/E move
- 7.5%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 58.44
- IV
- 76.1%
- B/E move
- 6.3%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 59.49
- IV
- 72.9%
- B/E move
- 5.0%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 60.44
- IV
- 70.8%
- B/E move
- 4.1%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 61.30
- IV
- 69.7%
- B/E move
- 3.6%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 62.17
- IV
- 68.7%
- B/E move
- 3.0%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 63.03
- IV
- 67.7%
- B/E move
- 2.5%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 63.89
- IV
- 66.7%
- B/E move
- 1.9%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 64.76
- IV
- 65.6%
- B/E move
- 1.4%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 68.02
- IV
- 84.6%
- B/E move
- 1.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 51.86% | |
| 50.60% | |
| 54.56% | |
| 50.14% | |
| 51.37% | |
| 49.44% | |
| 53.22% | |
| 54.19% | |
| 57.07% | |
| 57.88% |
Biotechnology
VERA
Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases in the United…
More →VERU
Veru Inc., an oncology biopharmaceutical company, focuses on the development of drugs for the treatment of cancers. The company is headquartered in Miami, Florida.
More →VIR
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San…
More →VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered…
More →VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is…
More →VOR
Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. The company is headquartered in…
More →